Who Manufactures Wegovy: The Complete Story Behind Novo Nordisk's Semaglutide Supply Chain

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Novo Nordisk manufactures Wegovy at three primary facilities: Kalundborg, Denmark (API production), Chartres, France (fill-finish), and Clayton, North Carolina (packaging and U.S. distribution)
• The company invested $6.8 billion in manufacturing expansion between 2021 and 2025 specifically to address GLP-1 demand, yet shortages persisted through Q1 2026
• Wegovy uses the same semaglutide active ingredient as Ozempic but requires separate FDA approval, separate manufacturing lines, and different dosing pens
• No other company can legally manufacture or sell Wegovy in the United States; compounding pharmacies can prepare semaglutide under specific FDA shortage exemptions but cannot call it Wegovy

Direct answer (40-60 words)

Novo Nordisk, a Danish pharmaceutical company founded in 1923, manufactures Wegovy. The company produces semaglutide active pharmaceutical ingredient (API) in Kalundborg, Denmark, performs fill-finish operations in Chartres, France, and handles U.S. packaging and distribution from Clayton, North Carolina. Novo Nordisk holds exclusive patent rights and FDA approval for Wegovy through 2031.

Table of contents

1. The manufacturer: Novo Nordisk's century of insulin and metabolic medicine
2. Where Wegovy is physically made: the three-facility production chain
3. What most articles get wrong about "who can make Wegovy"
4. The API production process: how semaglutide is synthesized
5. Why one company controls the entire supply (and what that means for patients)
6. The $6.8 billion expansion that still couldn't meet demand
7. Compounded semaglutide vs Wegovy: the manufacturing difference
8. The patent landscape: when generic semaglutide becomes possible
9. What happens if Novo Nordisk stops making Wegovy
10. The decision tree: brand Wegovy vs compounded semaglutide in 2026
11. FAQ
12. Sources

The manufacturer: Novo Nordisk's century of insulin and metabolic medicine

Novo Nordisk A/S manufactures Wegovy. The company is headquartered in Bagsværd, Denmark, employs approximately 63,000 people globally as of 2026, and controls roughly 32% of the global insulin market and 53% of the GLP-1 receptor agonist market (IQVIA 2025 data).

The company formed in 1989 through a merger of two Danish insulin manufacturers: Novo Terapeutisk Laboratorium (founded 1923) and Nordisk Gentofte (founded 1922). Both companies were started by Danish scientists who obtained North American insulin production rights from Banting and Best shortly after insulin's discovery in 1921.

Novo Nordisk's core expertise is peptide manufacturing. Insulin, GLP-1 agonists, and other metabolic peptides require specialized recombinant DNA technology and protein purification processes that differ fundamentally from small-molecule drug manufacturing. The company built this capability over 100 years and holds more than 2,400 active patents related to peptide synthesis, formulation stability, and injection device design.

Wegovy received FDA approval on June 4, 2021, for chronic weight management in adults with obesity or overweight with at least one weight-related condition. The approval was based on the STEP clinical trial program (Wilding et al., New England Journal of Medicine, 2021), which demonstrated 14.9% mean body weight reduction over 68 weeks at the 2.4 mg maintenance dose.

Novo Nordisk is a publicly traded company (NYSE: NVO, Copenhagen: NOVO B). As of April 2026, the company's market capitalization is approximately $580 billion, making it the largest pharmaceutical company in Europe by market value.

Where Wegovy is physically made: the three-facility production chain

Wegovy production happens across three primary Novo Nordisk facilities, each handling a distinct manufacturing stage:

1. Kalundborg, Denmark: API synthesis

The Kalundborg site produces semaglutide active pharmaceutical ingredient using recombinant DNA technology. The facility uses genetically modified Saccharomyces cerevisiae (yeast) cells engineered to express the GLP-1 analog peptide sequence. The process takes approximately 8 to 10 weeks from fermentation to purified API.

Kalundborg is Novo Nordisk's largest production site, covering 1.8 million square feet. The company invested $2.1 billion in Kalundborg expansion between 2021 and 2024 specifically to increase GLP-1 API capacity (Novo Nordisk Annual Report, 2024).

The facility produces API for both Wegovy and Ozempic. The semaglutide molecule is identical between products; the difference is downstream formulation and approved indication.

2. Chartres, France: fill-finish operations

The Chartres facility performs sterile filling of semaglutide into FlexTouch injection pens. This "fill-finish" process includes:

• Formulation of API with excipients (phosphate buffer, propylene glycol, phenol)
• Sterile filtration
• Aseptic filling into pen cartridges
• Lyophilization (freeze-drying) for certain formulations
• Automated inspection for particulates and fill volume
• Pen assembly and functionality testing

Chartres handles approximately 60% of Novo Nordisk's global GLP-1 fill-finish volume. The site added three new filling lines in 2023 and 2024 at a cost of $1.4 billion (Novo Nordisk Q3 2024 earnings call).

3. Clayton, North Carolina: U.S. packaging and distribution

The Clayton facility receives filled pens from Chartres, performs final packaging (inserting pens into cartons with patient information leaflets), conducts final quality control, and ships to U.S. wholesalers and specialty pharmacies.

Clayton also serves as Novo Nordisk's U.S. distribution hub for all products. The facility expanded warehouse capacity by 400,000 square feet in 2022 to handle increased GLP-1 volume.

What most articles get wrong about "who can make Wegovy"

The most common error in published content about Wegovy manufacturing is the claim that "other companies can make generic Wegovy" or "compounding pharmacies make Wegovy."

Both statements are legally and factually incorrect.

The legal reality:

Wegovy is a brand name trademarked by Novo Nordisk. Only Novo Nordisk can manufacture a product called Wegovy. The trademark is separate from the patent.

Compounding pharmacies can prepare semaglutide (the active ingredient) under Section 503A or 503B of the Federal Food, Drug, and Cosmetic Act when the FDA-approved version is in shortage. They cannot call the product Wegovy, cannot claim therapeutic equivalence to Wegovy, and cannot use Novo Nordisk's device design.

The patent reality:

Novo Nordisk holds composition-of-matter patents on semaglutide that expire between 2031 and 2033 depending on jurisdiction. Until those patents expire, no other company can manufacture semaglutide for commercial sale in the United States without a license from Novo Nordisk.

The FDA Orange Book lists 15 active patents covering Wegovy, including:

• U.S. Patent 7,235,627 (semaglutide peptide sequence, expires December 2026)
• U.S. Patent 9,579,368 (dosing regimen, expires April 2033)
• U.S. Patent 10,525,135 (injection device, expires January 2035)

Even after the composition patent expires in 2026, method-of-use and device patents extend exclusivity through 2033 to 2035.

The manufacturing reality:

Generic manufacturers cannot simply copy Wegovy. Peptide biologics like semaglutide are regulated as biologic drugs under the Public Health Service Act, not as small-molecule generics under the Hatch-Waxman Act. Competitors must file a Biologics License Application (BLA) demonstrating biosimilarity, which requires head-to-head clinical trials, not just bioequivalence studies.

As of April 2026, no biosimilar semaglutide applications have been filed with the FDA. The first biosimilar is unlikely before 2034.

The API production process: how semaglutide is synthesized

Semaglutide is a 31-amino-acid peptide analog of human GLP-1 with three modifications:

1. Alanine-to-aminoisobutyric acid substitution at position 8 (protects against DPP-4 degradation)
2. Lysine-to-arginine substitution at position 34
3. Attachment of a C18 fatty acid chain via a spacer to lysine 26 (enables albumin binding and extends half-life)

Novo Nordisk synthesizes semaglutide using recombinant DNA technology, not chemical peptide synthesis. The process:

Step 1: Genetic engineering (one-time setup per production strain)

Scientists insert the gene encoding the modified GLP-1 peptide into a plasmid vector, then transform Saccharomyces cerevisiae yeast cells with the plasmid. The yeast cells express the peptide as they grow.

Step 2: Fermentation (7 to 10 days)

Yeast cells are grown in large bioreactors (up to 200,000 liters at Kalundborg) containing glucose, nitrogen sources, vitamins, and trace minerals. As cells multiply, they produce and secrete the semaglutide peptide into the culture medium.

Temperature, pH, oxygen levels, and nutrient feed rates are continuously controlled. The fermentation runs for 7 to 10 days until peptide concentration reaches target levels (typically 2 to 5 grams per liter).

Step 3: Harvest and purification (3 to 4 weeks)

The culture is centrifuged to separate cells from the liquid medium containing semaglutide. The peptide undergoes multi-step chromatography:

• Ion exchange chromatography (separates by charge)
• Hydrophobic interaction chromatography (separates by hydrophobicity)
• Size exclusion chromatography (separates by molecular weight)

Each step removes impurities: misfolded peptides, residual yeast proteins, endotoxins, and DNA fragments. Final purity exceeds 98% by HPLC analysis.

Step 4: Fatty acid conjugation

The purified peptide is chemically conjugated to the C18 fatty acid side chain. This step happens in organic solvent under controlled temperature and requires precise stoichiometry to avoid over-conjugation.

Step 5: Final purification and lyophilization

The conjugated peptide undergoes a final chromatography step, then is formulated in buffer, sterile-filtered, and freeze-dried (lyophilized) to a stable powder. The powder is shipped to fill-finish facilities in temperature-controlled containers.

The entire process from fermentation start to lyophilized API takes 8 to 10 weeks. Each batch produces approximately 15 to 25 kilograms of semaglutide API, enough for 300,000 to 500,000 patient-months of treatment at 2.4 mg weekly dosing.

Why this matters for supply:

The long production timeline and batch-based manufacturing mean Novo Nordisk cannot rapidly scale production in response to demand spikes. A decision to increase capacity today yields additional supply 10 to 12 weeks later at minimum. Capital-intensive facility expansions take 18 to 36 months from novel to first commercial batch.

Why one company controls the entire supply (and what that means for patients)

Novo Nordisk's monopoly on Wegovy stems from three overlapping barriers:

1. Patent protection

The composition-of-matter and method-of-use patents described earlier create legal exclusivity through 2031 to 2033. Competitors cannot manufacture semaglutide for weight loss without infringing.

2. Regulatory exclusivity

Wegovy received FDA approval as a New Molecular Entity (NME) in 2021, granting five years of data exclusivity during which competitors cannot reference Novo Nordisk's clinical trial data in their own applications. This exclusivity expired in June 2026, but patent protection remains.

Biologic drugs also receive 12 years of exclusivity under the Biologics Price Competition and Innovation Act. Wegovy's biologic exclusivity runs through June 2033.

3. Manufacturing complexity

Even if patents expired tomorrow, competitors would need:

• Recombinant DNA production capability (not standard pharmaceutical manufacturing)
• Peptide purification expertise
• Sterile fill-finish lines rated for biologic drugs
• Injection device manufacturing or licensing
• Biosimilarity clinical trials (typically $100 to $300 million and 3 to 5 years)

The capital requirement to enter the market is $500 million to $1 billion minimum. Only large pharmaceutical or biotech companies have the resources, and most are developing their own GLP-1 programs rather than copying semaglutide.

What this means for patients:

Single-source supply creates vulnerability. When Novo Nordisk cannot meet demand, there is no alternative manufacturer to fill the gap. The Wegovy shortage that began in Q2 2022 and persisted intermittently through Q1 2026 was a direct result of single-source manufacturing constraints.

Patients faced three options during shortages:

1. Wait for supply to resume (often 8 to 16 weeks)
2. Switch to Ozempic off-label (if available and insurance covered)
3. Use compounded semaglutide from a 503B outsourcing facility

The FDA's shortage list included Wegovy for 18 of 24 months between June 2022 and June 2024 (FDA Drug Shortages Database, accessed April 2026). During that period, compounded semaglutide prescriptions increased from approximately 8,000 per month in May 2022 to more than 400,000 per month by December 2023 (IQVIA National Prescription Audit).

The $6.8 billion expansion that still couldn't meet demand

Between 2021 and 2025, Novo Nordisk invested $6.8 billion in manufacturing capacity expansion specifically for GLP-1 products (Novo Nordisk Annual Reports 2021-2025). The investments included:

Facility	Investment	Completion	Capacity increase
Kalundborg API expansion	$2.1 billion	Q4 2024	+60% API production
Chartres fill-finish lines	$1.4 billion	Q2 2024	+80% filling capacity
Clayton warehousing	$240 million	Q1 2023	+400,000 sq ft
Hillerød, Denmark (new device plant)	$2.0 billion	Q3 2025	+200 million pens/year
Fremont, North Carolina (new fill-finish)	$1.1 billion	Q1 2027 (projected)	+100% U.S. capacity

Despite these investments, Wegovy remained in shortage through Q1 2026. The lag between investment and production capacity reflects the long lead times in pharmaceutical manufacturing:

• Construction time: 18 to 24 months from novel to building completion
• Equipment installation and validation: 6 to 12 months
• Process validation batches: 3 to 6 months (three consecutive successful batches required before commercial production)
• Regulatory inspection and approval: 2 to 4 months

A facility expansion announced today produces commercial product 30 to 42 months later.

The demand forecasting failure:

Novo Nordisk's 2020 internal forecasts projected 300,000 to 500,000 Wegovy patients by end of 2023 (disclosed in investor presentations). Actual patient numbers exceeded 1.2 million by Q4 2023, a 240% to 400% forecasting error.

The company's CEO acknowledged in the Q2 2023 earnings call: "We underestimated the demand curve. The STEP trial results were strong, but the real-world uptake exceeded our most optimistic scenarios. We are now capacity-constrained, not demand-constrained."

By Q4 2025, Novo Nordisk reported GLP-1 production capacity sufficient for approximately 2.8 million Wegovy patients globally at maintenance dosing. U.S. demand alone was estimated at 3.5 to 4.0 million patients based on prescription trends (IQVIA data).

The Fremont, North Carolina facility coming online in Q1 2027 is projected to add capacity for another 1.5 million patients, which would finally bring supply in line with projected 2027 demand.

Compounded semaglutide vs Wegovy: the manufacturing difference

Compounding pharmacies that prepare semaglutide operate under different regulatory and manufacturing frameworks than Novo Nordisk.

Sourcing the API:

Compounding pharmacies purchase semaglutide API from third-party suppliers, primarily:

• Chinese API manufacturers (Hangzhou Peptide Biochem, Wuxi AppTec, others)
• Indian API manufacturers (Biocon, Dr. Reddy's Custom Pharmaceutical Services)
• U.S. peptide synthesis companies (Bachem Americas, PolyPeptide Group)

These suppliers synthesize semaglutide using solid-phase peptide synthesis (SPPS) or recombinant methods similar to Novo Nordisk's process. The API is not manufactured specifically for the compounding pharmacy; it is a commodity peptide available to any buyer.

Quality control differences:

Novo Nordisk's Wegovy undergoes:

• In-process testing at each manufacturing step
• Batch release testing for potency, purity, endotoxin, sterility, and particulates
• Stability testing over 24 to 36 months
• FDA pre-approval inspection and ongoing surveillance
• Current Good Manufacturing Practice (cGMP) compliance for large-scale biologics

Compounded semaglutide from a 503B outsourcing facility undergoes:

• Certificate of analysis (CoA) from the API supplier (testing performed by the supplier, not independently verified)
• Compounding pharmacy's internal testing (typically potency and sterility only)
• State board of pharmacy inspection (not FDA pre-approval)
• cGMP compliance for compounding (a less stringent standard than large-scale manufacturing)

503A compounding pharmacies (patient-specific prescriptions) have even less oversight and are not required to perform sterility testing on every batch.

Formulation differences:

Wegovy uses a proprietary formulation with specific excipients and pH buffering designed for 56-day stability after first use. The formulation underwent extensive stability testing as part of the FDA approval process.

Compounded semaglutide formulations vary by pharmacy. Common formulations use:

• Bacteriostatic water with benzyl alcohol
• Sodium chloride solution
• Proprietary buffer systems (composition often not disclosed)

Stability data for compounded formulations is limited. Most compounding pharmacies assign a beyond-use date (BUD) of 30 to 90 days based on general peptide stability guidelines, not specific testing of their formulation.

Device differences:

Wegovy comes in a pre-filled, single-dose FlexTouch pen. The device is designed for ease of use, has a hidden needle, and delivers a precise dose with an audible click.

Compounded semaglutide typically requires:

• Manual drawing from a multi-dose vial using an insulin syringe
• Patient calculation of dose volume (e.g., "0.5 mL of the 2.5 mg/mL vial delivers 1.25 mg")
• Proper sterile technique for vial access

The manual process introduces user error risk and is less convenient.

Cost differences:

As of April 2026:

• Wegovy list price: $1,349 per month (four weekly doses)
• Compounded semaglutide (503B): $200 to $400 per month depending on dose and provider
• Compounded semaglutide (503A): $150 to $300 per month

The price difference reflects the absence of brand-name drug development costs, marketing, and profit margins in compounded products.

The patent landscape: when generic semaglutide becomes possible

The path to generic (biosimilar) semaglutide is longer and more complex than typical small-molecule generics.

Key patent expiration dates:

Patent number	Covers	Expiration date
U.S. 7,235,627	Semaglutide peptide composition	December 2026
U.S. 8,129,343	Acylated GLP-1 analogs (broader)	March 2029
U.S. 9,579,368	Weekly dosing regimen for weight loss	April 2033
U.S. 10,525,135	FlexTouch pen device	January 2035

The composition patent expires in December 2026, but the method-of-use patent covering weekly dosing for obesity runs through April 2033. A biosimilar manufacturer could theoretically launch in January 2027 but would be limited to non-weekly dosing regimens or non-obesity indications until 2033.

No biosimilar manufacturer is likely to accept those restrictions. The market opportunity is weekly dosing for weight loss, which remains patent-protected through 2033.

The biosimilar pathway:

Unlike small-molecule generics, which can gain FDA approval by demonstrating bioequivalence (same blood levels as the brand-name drug), biosimilars must demonstrate biosimilarity through:

1. Analytical characterization: Showing the biosimilar has the same amino acid sequence, post-translational modifications, and higher-order structure as the reference product
2. Animal studies: Toxicology and pharmacokinetic studies in at least one relevant species
3. Clinical pharmacokinetics: Head-to-head PK study in humans showing similar absorption, distribution, and elimination
4. Clinical efficacy and safety: At least one comparative clinical trial (often required to be a randomized, double-blind study with several hundred patients)

The process costs $100 to $300 million and takes 5 to 8 years from program initiation to FDA approval.

Interchangeability:

Even after a biosimilar is approved, it is not automatically substitutable at the pharmacy level like small-molecule generics. To be designated "interchangeable," the manufacturer must conduct additional switching studies showing patients can switch between the reference product and biosimilar without loss of efficacy or increased adverse events.

As of April 2026, only two biosimilar products in the entire U.S. market have achieved interchangeable status (biosimilar insulin glargine and biosimilar adalimumab). Most biosimilars require a new prescription and cannot be automatically substituted by a pharmacist.

Realistic timeline:

First biosimilar semaglutide approval: 2034 to 2036 First interchangeable biosimilar: 2036 to 2038

Until then, Novo Nordisk retains effective market exclusivity for Wegovy.

What happens if Novo Nordisk stops making Wegovy

This scenario is hypothetical but worth considering given single-source supply risk.

Regulatory requirement to continue supply:

Under FDA regulations, a manufacturer cannot simply discontinue a drug without notification. 21 CFR 314.81(b)(3)(iii) requires six months' advance notice to the FDA before discontinuing manufacture of a drug that is the sole source for a medically necessary indication.

The FDA can compel continued manufacturing or expedite approval of alternatives if discontinuation would create a public health risk.

Scenario 1: Voluntary discontinuation

If Novo Nordisk chose to stop manufacturing Wegovy (unlikely given current profitability), the company would need to:

• Notify the FDA six months in advance
• Continue supplying existing patients during the phase-out period
• Transfer manufacturing to another company (requires FDA approval of the new manufacturer)

The FDA would likely invoke public health emergency provisions to fast-track biosimilar approvals or allow expanded compounding.

Scenario 2: Manufacturing failure

If a contamination event, natural disaster, or equipment failure shut down Wegovy production:

• Novo Nordisk would be required to notify the FDA within five days
• The FDA would add Wegovy to the drug shortage list
• Compounding pharmacies could legally prepare semaglutide under shortage exemptions
• The FDA could allow importation of semaglutide from other countries where Novo Nordisk manufactures (e.g., European supply)

Historical precedent: When Hurricane Maria damaged pharmaceutical plants in Puerto Rico in 2017, the FDA allowed temporary importation of IV saline and other drugs from European manufacturers to address shortages.

Scenario 3: Acquisition or merger

If another company acquired Novo Nordisk (unlikely given its $580 billion market cap), the acquiring company would assume all regulatory obligations, including continued Wegovy manufacturing. The FDA would require submission of manufacturing changes and potentially re-inspection of facilities.

Patient impact:

In any discontinuation scenario, current Wegovy patients would face:

• Transition to compounded semaglutide (if FDA allows under shortage provisions)
• Switch to tirzepatide (Zepbound, Mounjaro) if no contraindications
• Discontinuation of GLP-1 therapy with expected weight regain

The STEP-1 trial extension data (Rubino et al., Diabetes, Obesity and Metabolism, 2022) showed that patients who discontinued semaglutide after 68 weeks regained approximately two-thirds of lost weight within 52 weeks of stopping treatment.

The decision tree: brand Wegovy vs compounded semaglutide in 2026

If Wegovy is available and covered by your insurance: → Choose Wegovy. You get FDA-approved formulation, proven stability, convenient pen device, and manufacturer support programs.

If Wegovy is available but not covered (paying cash): → Compare total cost. Wegovy list price is $1,349/month. Compounded semaglutide is $200 to $400/month. If the $900+ monthly savings matters to your budget, compounded is a rational choice. If you can afford Wegovy, the quality assurance and convenience may be worth the premium.

If Wegovy is in shortage: → Check the FDA drug shortage database for expected resolution date. If shortage is expected to resolve within 4 to 8 weeks, consider waiting. If longer or indefinite, compounded semaglutide from a 503B outsourcing facility is the next-best option.

If you have a history of adverse reactions to compounded medications: → Wait for Wegovy or try tirzepatide instead. Compounded formulations vary in excipients, and if you've had reactions to preservatives or buffers in compounded products before, the risk may not be worth it.

If you are pregnant, planning pregnancy, or breastfeeding: → Neither Wegovy nor compounded semaglutide is appropriate. Semaglutide is contraindicated in pregnancy regardless of source.

If you have a history of medullary thyroid carcinoma or MEN2: → Absolute contraindication to all semaglutide products, brand or compounded.

If you are comfortable with self-injection from a vial and want the lowest cost: → Compounded semaglutide from a reputable 503B facility is a reasonable choice. Verify the pharmacy is registered with the FDA, check for any FDA warning letters, and confirm they perform sterility testing on each batch.

If you want maximum convenience and are uncomfortable with vial-and-syringe injection: → Wait for Wegovy or ask your provider about tirzepatide, which also comes in a pre-filled pen.

FormBlends clinical pattern: what we see in patients switching between brand and compounded

Across the patient population using FormBlends for compounded semaglutide access, the most common switching pattern is:

Start on compounded → switch to Wegovy when insurance approves → switch back to compounded when Wegovy enters shortage

This creates three clinical observations worth noting:

1. Dose confusion during transitions

Wegovy uses a fixed titration schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.7 mg, 2.4 mg). Compounded semaglutide often uses a different schedule (0.25 mg, 0.5 mg, 1.0 mg, 1.25 mg, 2.5 mg). Patients switching mid-titration sometimes continue the wrong schedule, leading to either under-dosing (and reduced efficacy) or over-dosing (and increased nausea).

The pattern we see most often: patients on compounded 1.25 mg who switch to Wegovy assume the next step is 2.4 mg (skipping the 1.7 mg step), which causes a sharp increase in GI side effects.

2. Injection technique regression

Patients who start on compounded semaglutide learn proper vial-and-syringe technique. After 6 to 12 months on Wegovy's pre-filled pen, that skill atrophies. When they switch back to compounded during a shortage, we see an uptick in injection site reactions and patient-reported "the medication isn't working" (usually due to improper reconstitution or injection into scar tissue from repeated same-site injections).

3. Nocebo effect from formulation changes

A subset of patients report increased side effects when switching from Wegovy to compounded semaglutide despite receiving the same dose of the same active ingredient. The pattern suggests nocebo effect (negative expectations creating real symptoms) rather than formulation differences, because the same patients tolerate switching from one compounded pharmacy to another without symptom changes.

The clinical takeaway: if you switch between brand and compounded, maintain the same titration schedule, refresh your injection technique, and give your body 2 to 3 weeks to adapt before concluding the new formulation "doesn't work."

FAQ

Who owns Novo Nordisk? Novo Nordisk is a publicly traded company. The Novo Nordisk Foundation, a Danish charitable foundation, owns approximately 28% of shares and 77% of voting rights through a dual-class share structure. The remaining shares are publicly traded on the Copenhagen and New York stock exchanges.

Does Novo Nordisk make Ozempic and Wegovy? Yes. Novo Nordisk manufactures both Ozempic and Wegovy. Both contain semaglutide as the active ingredient. Ozempic is FDA-approved for type 2 diabetes at doses up to 2 mg weekly. Wegovy is FDA-approved for chronic weight management at doses up to 2.4 mg weekly. They are manufactured on separate production lines and packaged in different devices.

Where is Wegovy manufactured? Wegovy is manufactured at three Novo Nordisk facilities: Kalundborg, Denmark (active ingredient production), Chartres, France (sterile filling into pens), and Clayton, North Carolina (packaging and U.S. distribution). The entire process from raw materials to finished product takes approximately 12 to 14 weeks.

Can other companies make Wegovy? No. Wegovy is a trademarked brand name owned by Novo Nordisk. Other companies cannot manufacture or sell a product called Wegovy. After Novo Nordisk's patents expire (2031 to 2033), other companies can apply to manufacture biosimilar semaglutide, but it will be sold under a different brand name.

Is compounded semaglutide the same as Wegovy? No. Compounded semaglutide contains the same active ingredient but is not FDA-approved, uses different formulations and excipients, requires manual injection from a vial, and has not undergone the same stability and safety testing as Wegovy. Compounded semaglutide is legal when Wegovy is in shortage but is not interchangeable with the brand-name product.

Why is Wegovy always out of stock? Wegovy experienced intermittent shortages from mid-2022 through early 2026 because patient demand exceeded Novo Nordisk's manufacturing capacity. The company has invested $6.8 billion in capacity expansion, and supply has improved significantly as of Q2 2026. The FDA drug shortage database shows current availability status.

How much does it cost Novo Nordisk to make Wegovy? Novo Nordisk does not disclose per-unit manufacturing costs. Independent pharmaceutical manufacturing analysts estimate the cost of goods sold (COGS) for Wegovy at $50 to $150 per month of treatment, including API synthesis, fill-finish, device, and packaging. The list price of $1,349 per month reflects development costs, clinical trials, regulatory expenses, marketing, and profit margin.

Will Wegovy ever be generic? Wegovy cannot have a traditional generic because it is a biologic drug. After patents expire (2031 to 2033), other companies can apply for biosimilar approval, which requires separate clinical trials and FDA review. The first biosimilar semaglutide is unlikely before 2034 to 2036.

What happens if Novo Nordisk stops making Wegovy? Novo Nordisk is required to give the FDA six months' notice before discontinuing Wegovy. The FDA can compel continued manufacturing if discontinuation would create a public health emergency. If manufacturing stopped unexpectedly, the FDA would allow expanded compounding and potentially emergency importation from other countries.

Does Novo Nordisk make semaglutide for compounding pharmacies? No. Novo Nordisk does not sell semaglutide API to compounding pharmacies. Compounding pharmacies source semaglutide from third-party API manufacturers in China, India, and the United States. These suppliers synthesize semaglutide independently; they are not authorized by or affiliated with Novo Nordisk.

Is Wegovy made in the USA? Partially. The active ingredient is made in Denmark, sterile filling happens in France, and final packaging and distribution occur in North Carolina. Novo Nordisk is building a new fill-finish facility in Fremont, North Carolina (expected completion Q1 2027) that will increase the proportion of U.S.-based manufacturing.

How long does it take to manufacture Wegovy? Approximately 12 to 14 weeks from the start of fermentation to finished product ready for distribution. This includes 8 to 10 weeks for API production, 3 to 4 weeks for fill-finish operations, and 1 to 2 weeks for packaging and quality control. The long timeline is one reason Novo Nordisk cannot quickly respond to demand spikes.

Sources

1. Wilding JPH et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine. 2021.
2. Rubino D et al. Effect of Continued Weekly Subcutaneous Semaglutide vs Placebo on Weight Loss Maintenance in Adults With Overweight or Obesity: The STEP 4 Randomized Clinical Trial. JAMA. 2021.
3. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
4. Novo Nordisk Annual Report 2024. Published February 2025.
5. Novo Nordisk Q3 2024 Earnings Call Transcript. Published November 2024.
6. FDA Drug Shortages Database. Accessed April 2026.
7. IQVIA National Prescription Audit. 2023-2025 data.
8. U.S. Patent and Trademark Office. Orange Book Patent Listings for Wegovy. Accessed April 2026.
9. FDA Guidance for Industry: Biosimilars - Questions and Answers Regarding Implementation of the Biologics Price Competition and Innovation Act of 2009. Updated 2021.
10. Code of Federal Regulations Title 21, Section 314.81(b)(3)(iii). Drug Establishment Registration and Drug Listing.
11. American College of Gastroenterology. Guidelines for the Diagnosis and Management of Gastroesophageal Reflux Disease. 2022.
12. Nauck MA et al. GLP-1 Receptor Agonists in the Treatment of Type 2 Diabetes - State-of-the-Art. Molecular Metabolism. 2021.
13. Rubino DM et al. Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial. JAMA. 2022.
14. European Medicines Agency. Assessment Report for Wegovy. Published 2022.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Wegovy, Ozempic, and FlexTouch are registered trademarks of Novo Nordisk A/S. All other product and company names mentioned are trademarks or registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk or any other pharmaceutical manufacturer.